ORLANDO (EGMN) - The monoclonal antibody panitumumab extended progression-free survival and overall survival, each by a median of 2 months, when added to second-line treatment of metastatic colorectal cancer in patients with wild-type KRAS tumors, investigators reported. Patients with KRAS mutations did not benefit from the addition of panitumumab (Vectibix) to a FOLFIRI regimen in the phase III trial, which enrolled more than 1,100 patients, Dr. Marc Peeters said at a meeting on gastrointestinal...